MA Boston의 흑색종 임상 시험
흑색종 관련 연구 25개가 Boston 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
피험자 모집 중1/2상
- Call for Information (Investigational Site 0026), Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
피험자 모집 중1상
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
피험자 모집 중2상
- Local Institution - 0124, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
피험자 모집 중2상
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
피험자 모집 중1/2상
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
피험자 모집 중1/2상
- Tufts Medical Center, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
피험자 모집 중2상
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
피험자 모집 중1/2상
- Massachusetts General Hospital Cancer Institute, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
피험자 모집 중2상
- Massachusetts General Hospital Cancer Center, Boston
Project: Every Child for Younger Patients With Cancer
피험자 모집 중관찰 연구
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
피험자 모집 중1/2상
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
피험자 모집 중1/2상
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
피험자 모집 중1/2상
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
피험자 모집 중3상
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
피험자 모집 중2/3상
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
피험자 모집 중2/3상
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
피험자 모집 중3상
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
피험자 모집 중1상
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
피험자 모집 중1/2상
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
피험자 모집 중2상
- Dana Farber Cancer Institute, Boston
다른 도시의 흑색종 시험
- Houston, TX연구 61개
- New York City, NY연구 41개
- Nashville, TN연구 34개
- Los Angeles, CA연구 34개
- Pittsburgh, PA연구 31개
- St. Louis, MO연구 23개
- Durham, NC연구 22개
- Philadelphia, PA연구 22개
- Tampa, FL연구 21개
- Columbus, OH연구 21개
- Dallas, TX연구 21개
- San Francisco, CA연구 21개
Boston의 다른 연구
- 유방암연구 110개
- 암 (전체)연구 90개
- 비소세포폐암연구 87개
- 폐암연구 63개
- 대장직장암연구 62개
- 난소암연구 62개
- 전이성 암연구 61개
- 전립선암연구 56개
- 자궁내막암연구 51개
- 우울증연구 50개
- 심부전연구 46개
- 다발성 골수종연구 45개
ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.